Recombinant factor VIIa (NovoSeven®) and the safety of treatment

Seminars in Hematology

Volumn 38, Issue 4 SUPPL. 12, 2001, Pages 48-50

  Roberts, Harold R ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXPERIENCE; HEMOPHILIA; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; THROMBOSIS;

EID: 0035198825     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90148-9     Document Type: Conference Paper

References (22)

1. rFVIIa - Its thrombogenicity
2. Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery
3. Recombinant factor VIIa in Glanzmann's thromboasthenia: A potential therapeutic place
4. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin (II)-6 and II-8 release in healthy human subjects
5. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study
6. Factor VIIa in the treatment of haemophilia
7. Recombinant activated factor VII in the treatment of bleeding disorders
8. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy
9. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII
10. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa
11. Acute myocardial infarction complicating therapy with FVIII followed by APCC and Rfviia in a 26-year old man with haemophilia A and FVIII inhibitor
12. The use of NovoSeven® for profuse bleedings in surgical patients
13. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors
14. A randomised, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle, and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors
15. The use of NovoSeven® for adjunctive haemorrhage control in trauma patients
16. A possible mechanism of action of activated factor VII independent of tissue factor
17. Clinical experience with activated factor VII: Focus on safety aspects
18. Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A
19. Safety, efficacy, and lessons from continuous infusion with rFVIIa
20. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery
21. Disseminated intravascular coagulation and infusion of factor-VIII-inhibitor bypassing activity
22. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: Complete gene deletions confer the highest risk